Oncolytics Biotech Inc. (ONCY)

[onco_investor]

ASCO 2010 Posters Listed for Reovirus

The Phase II H&N trial data being presented is from the trial that led to the pivotal Phase III trial Oncolytics is getting ready to announce start of enrolment any day now.

The NSCLC data will most likely be interim data but could be very compelling... I cant wait for these results to be made public.

http://meetingplanner.asco.org/
Search Keyword - Reovirus

Developmental Therapeutics - Experimental Therapeutics
Monday, June 7 at 8:00 AM - 12:00 PM

S Hall A2

#3080: A phase I/II study of oncolytic reovirus plus carboplatin/ paclitaxel in patients with advanced solid cancers with emphasis on squamous cell carcinoma of the head and neck (SCCHN).

Eleni M Karapanagiotou


Trials in Progress Poster Session

Clinical Trials, Special Session
Monday, June 7 at 8:00 AM - 12:00 PM

S Hall A2

#TPS253: Phase I/II trial of reovirus serotype 3-Dearing strain in patients with recurrent ovarian cancer.

Dr. Elaine Lam

#TPS292: Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors.


Phase II Head and Neck - UK

Phase II Study of Intravenous Administration of a Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck.

http://www.oncolyticsbiotech.com/clinicaltrial_REO_011_Phase_II.html

Dr. Karapanagiotou was the first author in a poster presentation on the H&N trial in Nov 09. she was listed as affiliated with Royal Marsden. It appears that Dr. Karapanagiotou and Dr. Harrington have collaborated for years


Phase 1/2 NCI sponsored Ovarian Cancer trial at Ohio State Univ

A Phase 1/2 Study of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) (NSC 729968) in Patients With Ovarian, Primary Peritoneal and Fallopian Tube Carcinoma

http://www.oncolyticsbiotech.com/clinicaltrial013.html

Elaine Lam. The Ohio State University Department of Internal Medicine, Columbus, OH. Current Position: Fellow in Hem Onc at OSU

Noteworthy Accomplishments: Elaine received an award for the ASCO/AACR "Methods in Clinical Cancer Research: workshop award in Vail, CO in August 2009 based on her work on our study exploring the role or Reolysin in Pancreatic Cancer.

Phase II NSCLC with K-RAS or EGFR-activated tumors

http://www.oncolyticsbiotech.com/clinicaltrial_REO_016.html

Phase II Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors

The primary objectives of the Phase II trial are to determine the objective response rate of REOLYSIN® in combination with paclitaxel and carboplatin in patients with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, and to measure progression-free survival at 6 months. The secondary objectives are to determine the median survival and duration of progression-free survival in patients, and to evaluate the safety and tolerability of REOLYSIN® in combination with paclitaxel and carboplatin in this patient population.

The Principal Investigator is Dr. Miguel Villalona-Calero, Professor, Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center.



The abstracts for "General Poster Sessions" (including the one for the Phase I/II UK H&N Reolysin Trial) will be publicly released on ASCO.org on Thursday, May 20, at 6:00 PM (EDT).

http://chicago2010.asco.org/Abstracts/2010Abstracts.aspx

The recurrent ovarian cancer Reolysin Trial poster, and the Phase II Ras+ NSCLC Reolysin poster, will not be released until the presentation day of these "Trials in Progress Poster Session" presentations (Mon June 7).